Recent 8-K filings for AMPH

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42

  Net revenues flat at $171.2M vs $170.5M YoY.

• February 26, 2026, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74

  Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.

• January 12, 2026, 6:59 PM ET other material materiality 0.70 positive item 1.01item 7.01item 9.01 ◈ Material Agreements ×3

  Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal

  Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96

  Net revenues of $191.8M, flat YoY vs $191.2M.

• August 12, 2025, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 7.01item 9.01

  Amphastar licenses three novel peptides from Anji for up to $453M total

  Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%

  Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).

• May 7, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74

  Net revenues $170.5M, down from $171.8M in Q1 2024.

• February 27, 2025, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86

  Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).

• November 6, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96

  Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.

• August 7, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY

  Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.

• May 8, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04

  Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event earnings

7 positive 5 negative 9 neutral

source · AMPH on sec.gov